Results 31 to 40 of about 78,382 (206)

Harnessing autophagy to overcome mitogen‐activated protein kinase kinase inhibitor‐induced resistance in metastatic melanoma [PDF]

, 2019
Background Patients with malignant melanoma often relapse after treatment with BRAF and/or mitogen‐activated protein kinase kinase (MEK) inhibitors (MEKi) owing to development of drug resistance.
Alexander, M., Chaudhry, B., Edwards, N., Hill, David, Lovat, P.E., Plummer, R., Verykiou, S.   +6 more
core   +1 more source

miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma

Neoplasia: An International Journal for Oncology Research, 2020
BRAF inhibitors were approved for the treatment of BRAF-mutant melanoma. However, most patients acquire the resistance to BRAF inhibitors after several months of treatment.
Mai-Huong Thi Nguyen, Chen-Huan Lin, Szu-Mam Liu, Azusa Miyashita, Hironobu Ihn, Hsuan Lin, Chi Hou Ng, Jen-Chieh Tsai, Ming-Hong Chen, Mu-Shiun Tsai, In-Yu Lin, Shu-Chen Liu, Long-Yuan Li, Satoshi Fukushima, Jean Lu, Nianhan Ma   +15 more
doaj   +1 more source

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

BMC Cancer, 2021
Background While molecularly targeted therapies and immune checkpoint inhibitors have improved the prognosis of advanced melanoma, biomarkers are required to monitor drug responses.
Yukiko Kiniwa, Kenta Nakamura, Asuka Mikoshiba, Atsuko Ashida, Yasuyuki Akiyama, Atsushi Morimoto, Ryuhei Okuyama   +6 more
doaj   +1 more source

Severe Inflammatory Colitis Related to Encorafenib and Binimetinib following Immune Checkpoint Inhibitor Therapy

Case Reports in Gastroenterology, 2022
Encorafenib, a BRAF kinase inhibitor, in combination with binimetinib, a selective MEK inhibitor have known gastrointestinal adverse events; however, adverse colitis events have not been well studied.
Aaron G. Issac, David Szafron, Dongguang Wei, Jennifer L. McQuade, Yinghong Wang   +4 more
doaj   +1 more source

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction [PDF]

, 2018
The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
Bye, Alex P., Donaghy, Dillon, Gibbins, Jonathan M., Kriek, Neline, Osborne, Ashley A., Sage, Tanya, Unsworth, Amanda J.   +6 more
core   +4 more sources

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells. [PDF]

, 2014
BACKGROUND: The importance of the genetic background of cancer cells for the individual susceptibility to cancer treatments is increasingly apparent.
Arozarena, Imanol, Erice, O., Ferguson, J., Goicoechea, I., Margison, G.P., Wellbrock, C.   +5 more
core   +2 more sources

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma [PDF]

Neuro-Oncology Advances, 2020
BRAF-activating mutations have been detected in nearly all craniopharyngiomas of the papillary subtype, with interesting implications for patients with suboptimal tumor control. Here we report that combined treatment with BRAF and MEK inhibitors resulted in major clinical benefit in the case of a patient with a BRAF V600E-mutant papillary ...
Di Stefano, Anna Luisa, Guyon, David, Sejean, Karine, Feuvret, Loic, Villa, Chiara, Berzero, Giulia, Desforges Bullet, Virginie, Halimi, Emmanuel, Boulin, Anne, Baussart, Bertrand, Gaillard, Stephan   +10 more
openaire   +4 more sources

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

Cell Reports, 2013
Although BRAF and MEK inhibitors have proven clinical benefits in melanoma, most patients develop resistance. We report a de novo MEK2-Q60P mutation and BRAF gain in a melanoma from a patient who progressed on the MEK inhibitor trametinib and did not ...
Jessie Villanueva, Jeffrey R. Infante, Clemens Krepler, Patricia Reyes-Uribe, Minu Samanta, Hsin-Yi Chen, Bin Li, Rolf K. Swoboda, Melissa Wilson, Adina Vultur, Mizuho Fukunaba-Kalabis, Bradley Wubbenhorst, Thomas Y. Chen, Qin Liu, Katrin Sproesser, Douglas J. DeMarini, Tona M. Gilmer, Anne-Marie Martin, Ronen Marmorstein, David C. Schultz, David W. Speicher, Giorgos C. Karakousis, Wei Xu, Ravi K. Amaravadi, Xiaowei Xu, Lynn M. Schuchter, Meenhard Herlyn, Katherine L. Nathanson   +27 more
doaj   +1 more source

The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells. [PDF]

PLoS ONE, 2014
Although melanoma is the most aggressive skin cancer, recent advances in BRAF and/or MEK inhibitors against BRAF-mutated melanoma have improved survival rates.
Makoto Wada, Mano Horinaka, Toshikazu Yamazaki, Norito Katoh, Toshiyuki Sakai   +4 more
doaj   +1 more source

MicroRNAs in melanoma development and resistance to target therapy [PDF]

, 2017
microRNAs constitute a complex class of pleiotropic post-transcriptional regulators of gene expression involved in the control of several physiologic and pathologic processes.
Ascierto, Paolo Antonio, Ciliberto, Gennaro, Costantini, Susan, Croce, Carlo M, Fattore, Luigi, Malpicci, Debora, Mancini, Rita, Ruggiero, Ciro Francesco   +7 more
core   +1 more source